{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:51:04Z","timestamp":1778881864375,"version":"3.51.4"},"reference-count":61,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T00:00:00Z","timestamp":1482105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Intern Med"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment of classical Hodgkin's lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) has been a success story, with cure of localized disease with radiotherapy in the 1930s, cure of advanced stages with combination chemotherapy with\/without radiotherapy in the mid\u20101960s and continuous improvements since then. Nonetheless, at present approximately 2% of patients with classical <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> are primarily refractory to conventional therapy with only 50% becoming long\u2010term survivors. Another 13% of patients relapse, with only 60% being alive 10 years postrecurrence (as exemplified in this review in a Swedish cohort of 18\u2010 to 65\u2010year\u2010old patients diagnosed during the period 1992\u20132009). Recently, novel targeted drugs were approved for refractory\/relapsed <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> and here we review results of trials that form the basis for these approvals as well as new trials. In summary, brentuximab vedotin can be used in refractory patients (i) as a complement to high\u2010dose chemotherapy with autologous stem cell transplantation (<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) improving the chances of being able to proceed to an allogenic <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> and cure, (ii) as consolidation after autologous <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> and (iii) as palliative life\u2010prolonging treatment. However, we have yet to determine whether this drug provides the greatest benefit in first\u2010 or second\u2010line treatment, as consolidation or in refractory disease or relapse. Trials of immune checkpoint inhibitors, such as those targeting programmed death 1 (nivolumab and pembrolizumab), and thus not primarily the tumour cells, have shown overall response rates of &gt;65%. Long\u2010term results and data from Phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> trials are still lacking, but nivolumab recently gained approval in refractory patients already treated with brentuximab vedotin and autologous <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>. Other novel treatments of interest include T cells with a chimeric antigen receptor and combination therapies with histone deacetylase inhibitors.<\/jats:p>","DOI":"10.1111\/joim.12582","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T11:02:40Z","timestamp":1482145360000},"page":"247-260","source":"Crossref","is-referenced-by-count":28,"title":["Novel treatment concepts in Hodgkin lymphoma"],"prefix":"10.1111","volume":"281","author":[{"given":"I.","family":"Glimelius","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology Section of Clinical and Experimental Oncology Uppsala University Uppsala Sweden"},{"name":"Department of Medicine Clinical Epidemiology Unit Karolinska Institutet Karolinska University Hospital Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Diepstra","sequence":"additional","affiliation":[{"name":"Department of Pathology and Medical Biology University of Groningen University Medical Center Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,19]]},"reference":[{"key":"e_1_2_14_2_1","first-page":"B4485","article-title":"On the aetiology of Hodgkin lymphoma","volume":"59","author":"Hjalgrim H","year":"2012","journal-title":"Dan Med J"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24184"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi119"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2014.912277"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-015-0436-0"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.3.182"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.4.465"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-008-0018-6"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4444"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.07.002"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01652.x"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403992"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.0917"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13051"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1185789"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0076"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv256"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph8030607"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.018"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_14_30_1","unstructured":"SweetenhamJ WalewskiJ NadamaneeAet al.Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of RelapsePresented at the 57th American Society of Hematology (ASH) Annual Meeting Orlando FL December 5\u20108 2015."},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-644336"},{"key":"e_1_2_14_32_1","doi-asserted-by":"crossref","unstructured":"YasenchakCA Forero\u2010TorresA Cline\u2010BurkhardtVJMet al.Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi\u2010Cohort Phase 2 Study.Presented at the 57th American Society of Hematology (ASH) Annual Meeting Orlando FL December 5\u20108 2015.","DOI":"10.1182\/blood.V126.23.587.587"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_2_14_34_1","unstructured":"BorchmannP EichenauerDA PluetschowAet al.Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study.Presented at the 57th American Society of Hematology (ASH) Annual Meeting Orlando FL December 5\u20108 2015."},{"key":"e_1_2_14_35_1","doi-asserted-by":"crossref","unstructured":"ParkSI OlajideOA ReddyNMet al.A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non\u2010bulky Hodgkin lymphoma.2016 ASCO Annual Meeting J Clin Oncol 34 (suppl; abstr 7508) 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7508"},{"key":"e_1_2_14_36_1","unstructured":"SawasA ConnorsJM KuruvillaJGet al.The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T\u2010Cell Lymphoma (ALCL): Results of an International Multi Center Phase I\/II Experience.Presented at the 57th American Society of Hematology (ASH) Annual Meeting Orlando FL December 5\u20108 2015."},{"key":"e_1_2_14_37_1","unstructured":"LaCasceAS BociekG SawasAet al.Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma.Presented at the 57th American Society of Hematology (ASH) Annual Meeting Orlando FL December 5\u20108 2015."},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.167"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq622"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28712"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-561878"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_14_43_1","doi-asserted-by":"crossref","unstructured":"AnsellA ArmandP TimmermanJMet al.Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin Lymphoma (R\/R cHL): Clinical Outcomes from Extended Follow\u2010up of a Phase 1 Study (CA209\u2010039).Presented at the 57th American Society of Hematology (ASH) Annual Meeting Orlando FL December 5\u20108 abstract nr 583 2015.","DOI":"10.1182\/blood.V126.23.583.583"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_14_45_1","doi-asserted-by":"crossref","unstructured":"HatakeK KinoshitaT FukuharaNet al.Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO\u20104538\u201015): An interim analysis.2016 ASCO Annual Meeting J Clin Oncol 34 2016 (suppl; abstr e19018) 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.e19018"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.187"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_2_14_49_1","unstructured":"HerbauxC GauthierJ BricePet al.Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM\u2010TC.Presented at the 57th American Society of Hematology (ASH) Annual Meeting Orlando FL December 5\u20108 2015."},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7177"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_2_14_52_1","doi-asserted-by":"crossref","unstructured":"ChenRW ZinzaniPL FanaleMAet al.Pembrolizumab for relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL): phase 2 KEYNOTE\u2010087 study.2016 ASCO Annual Meeting J Clin Oncol 34 (suppl; abstr 7555) 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7555"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.06.011"},{"key":"e_1_2_14_54_1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.V126.23.2018.2018","article-title":"Safety and efficacy of allogeneic hematopoetic stem cell transplant (HSCT) after treatment with programmed cell death 1 (PD\u20101) inhibitors","volume":"126","author":"Merryman RW","year":"2015","journal-title":"Blood"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5304"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1906"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1468"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21664"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07963.x"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-362475"},{"key":"e_1_2_14_62_1","doi-asserted-by":"crossref","unstructured":"BairSM StrelecLE NastaSet al.Outcomes in patients with relapsed\/refractory Hodgkin lymphoma (RR\u2010HL) with progression after autologous stem cell transplantation in the current era of novel therapeutics.2016 ASCO Annual Meeting J Clin Oncol 34 (suppl; abstr 2543) 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.2543"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjoim.12582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/joim.12582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:36:29Z","timestamp":1695497789000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/joim.12582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,19]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/joim.12582"],"URL":"https:\/\/doi.org\/10.1111\/joim.12582","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,19]]}}}